Effects of Anticoagulation Intensity on Hemostatic Markers in Patients with Non-Valvular Atrial Fibrillation

Circulation Journal

Volumn 68, Issue 1, 2004, Pages 29-34

  Nozawa, Takashi ^a   Inoue, Hiroshi ^a   Iwasa, Atsushi ^b   Okumura, Ken ^b   Jong Dae, Lee ^c   Shimizu, Akibiko ^d   Hayano, Motonobu ^e   Yano, Katsusuke ^e  

^a UNIVERSITY OF TOYAMA   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c UNIVERSITY OF FUKUI   (Japan)

^d YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e NAGASAKI UNIVERSITY   (Japan)

Author keywords

Anticoagulants; Antiplatelet agents; Atrial fibrillation; Stroke prevention

Indexed keywords

ANTITHROMBOCYTIC AGENT; BETA THROMBOGLOBULIN; BIOCHEMICAL MARKER; D DIMER; FIBRIN; PROTHROMBIN FRAGMENT F1.2; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; ETHNOLOGY; FEMALE; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HUMAN; INTERNATIONAL STANDARD UNIT; MAJOR CLINICAL STUDY; MALE; SIDE EFFECT; SINUS RHYTHM; THROMBOEMBOLISM;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BETA-THROMBOGLOBULIN; BIOLOGICAL MARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEMOSTASIS; HUMANS; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PLATELET FACTOR 4; WARFARIN;

EID: 0942266121     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.68.29     Document Type: Article

References (30)

1. Wolf PA, Dawber TR, Thomas HE, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The Framingham study. Neurology 1978; 28: 973-977.
2. Narumiya T, Sakamaki T, Sato Y, Kanmatsuse K. Relationship between atrial appendage function and left atrial thrombus in patients with nonvalvular chronic atrial fibrillation and atrial flutter. Circ J 2003; 67: 68-72.
3. Gustafsson C, Blomback M, Britton M, Hamsten A, Svensson J. Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation. Stroke 1990; 21: 47-51.
4. Lip GYH, Lip PL, Zarifis J, Watson RDS, Bareford D, Lowe GDO, et al. Fibrin D-dimer and β-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation: Effects of introducing ultra-low-dose warfarin and aspirin. Circulation 1996; 94: 425-431.
5. Li-Saw-Hee FL, Blann AD, Lip GYH. Effects of low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation. Stroke 2000; 31: 828-833.
6. Lip GYH, Lowe GDO, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: Effects of warfarin treatment. Br Heart J 1995; 73: 527-533.
7. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-638.
8. The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med 1996; 156: 409-416.
9. Feinberg WM, Cornell ES, Nightingale SD, Pearce LA, Tracy RP, Hart RG, et al for the Stroke Prevention in Atrial Fibrillation Investigators. Relation between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke 1997; 28: 1101-1106.
10. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687-691.
11. Yamaguchi T for Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: A multicenter, prospective, randomized trial. Stroke 2000; 31: 817-821.
12. Takahashi H, Kashima T, Nomizo Y, Muramoto N, Shimizu T, Nasu K, et al. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998; 63: 519-528.
13. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-1511.
14. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, et al for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327: 1406-1412.
15. Kannel WB, Abbott RD, Savage DD, McNamara PM. Coronary heart disease and atrial fibrillation: The Framingham study. Am Heart J 1983; 106: 389-396.
16. Petersen P, Godtfredsen J. Embolic complications in paroxysmal atrial fibrillation. Stroke 1986; 17: 622-626.
17. Takahashi N, Seki A, Imataka K, Fujii J. Clinical features of paroxysmal atrial fibrillation: An observation of 94 patients. Jpn Heart J 1981; 22: 143-149.
18. Roy D, Marchand E, Gagne P, Chabot M, Cartier R. Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. Am Heart J 1986; 112: 1039-1043.
19. Inoue H, Atarashi H for the Research Group for Antiarrhythmic Drug Therapy. Risk factors for thromboembolism in patients with paroxysmal atrial fibrillation. Am J Cardiol 2000; 86: 852-855.
20. Lip GYH, Lowe GD, Rumley A, Dunn FG. Fibrinogen and fibrin-D-dimer levels in paroxysmal atrial fibrillation: Evidence for intermediate elevated levels of intravascular thrombogenesis. Am Heart J 1996; 131: 724-730.
21. Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: A study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol 1997; 29: 106-112.
22. Canepa-Anson R, Williams M, Marshall J, Mitsuoka T, Lightman S, Sutton R. Mechanism of polyuria and natriuresis in atrioventricular nodal tachycardia. BMJ 1984; 289: 866-868.
23. Boykin J, Cadnapaphornchai P, McDonald KM, Schrier RW. Mechanism of diuretics response associated with atrial tachycardia. Am J Physiol 1975; 229: 1486-1491.
24. Feinberg WM, Pearce LA, Hart RG, Cushman M, Cornell ES, Lip GYH, et al for the Stroke Prevention in Atrial Fibrillation Investigators. Markers of thrombin and platelet activity in patients with atrial fibrillation: Correlation with stroke among 1531 participants in the Stroke Prevention in Atrial Fibrillation III study. Stroke 1999; 30: 2547-2553.
25. Shah AB, Beamer N, Coull BM. Enhanced in vivo platelet activation in subtypes of ischemic stroke. Stroke 1985; 16: 643-647.
26. Minar E, Ehringer H, Jung M, Koppensteiner R, Stumpflen A. Lack of influence of low-dose acetylsalicylic acid (100mg daily) on platelet survival time, β-thromboglobulin and platelet factor 4 in patients with peripheral arterial occlusive disease. Thromb Res 1988; 52: 219-226.
27. Carrieri P, Orefice G, Indaco A. No effect of acetylsalicylic acid on β-thromboglobulin and platelet factor 4 plasma levels in patients with transient ischemic attacks. Stroke 1986; 17: 1153-1155.
28. Yamamoto K, Ikeda U, Fukazawa H, Shimada K. Effects of aspirin on status of thrombin generation in atrial fibrillation. Am J Cardiol 1996; 77: 528-530.
29. Taomoto K, Asada M, Kanazawa Y, Matsumoto S. Usefulness of the measurement of plasma β-thromboglobulin (β-TG) in cerebrovascular disease. Stroke 1983; 14: 518-524.
30. Handin RI, McDonough M, Lesch M. Elevation of platelet factor four in acute myocardial infarction: Measurement by radioimmunoassay. J Lab Clin Med 1978; 91: 340-349.